Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology
Avoids 4-1BB/OX-40 Toxicity Issues
Executive Summary
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
You may also be interested in...
Japan Enhertu Nod Another Boost For Daiichi's Oncology Hopes
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
GTS Alliance Gives Mochida A Cell Therapy Buy-In
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
Positive Evidence Stacks Up For Takeda's Dengue Vaccine
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.
Need a specific report? 1000+ reports available
Buy Reports